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Research
The immune system is a complex set of cellu-
lar, chemical, and soluble protein components 
that interact with each other in a sequential, 
regulated manner to protect the body against 
foreign substances. Early T-lymphocyte (T-cell) 
progenitors originate in the bone marrow and 
migrate to the thymus, where they differenti-
ate, undergo positive and negative selection, 
and mature, before being released into circu-
lation. Appropriate and carefully regulated 
apoptosis is one of the major mechanisms for 
homeostasis and the selection and development 
of fully competent T cells (Chaplin 2010). 
Recent efforts have sought to use transcrip-
tional profiling to discover genomic patterns 
that are predictive of toxicity and to investigate 
the molecular responses to chemical stressors 
(Auerbach et al. 2010; Boverhof et al. 2009). 
Identifying chemical-induced changes in 
gene expression would contribute to a deeper 
understanding of the molecular mechanisms 
of immunotoxicity and would allow for an 
assessment of the immune system within the 
confines of traditional toxicology studies.
Exposure to the immunosuppressive 
agents dexamethasone (DEX) (Marchetti 
et al. 2003; van Vliet et al. 1986), diethylstil-
bestrol (DES) (Gould et al. 2000), cyclophos-
phamide (CPS) (Luster et al. 1981; Wang and 
Cai 1999), and 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) (Camacho et al. 2005; Dean 
et al. 1985) results in hypocellularity, atrophy, 
and apoptosis in the thymus; however, the 
putative chemi  cal mechanisms of action and 
cellular targets differ (Luebke et al. 2006). 
The nitrogen mustard derivative CPS induces 
DNA mutation by alkylation and cross-linking 
(Wang and Cai 1999). DEX (Marchetti et al. 
2003) and DES (Ahmed 2000), synthetic hor-
mones that bind to the glucocorticoid and 
estrogen receptors, respectively, translocate 
to the nucleus bound to the receptors and 
regulate gene expression and protein synthesis. 
In the cytoplasm, DEX can bind to and inter-
fere with regulatory factors, disrupt the T-cell 
receptor (TCR) complex, and impair T-cell 
signaling (Lowenberg et al. 2007). In utero 
DES exposure has been associated with post-
natal alterations in T-cell and natural killer 
(NK) cell function and increased incidence of 
autoimmune diseases (Holladay 1999).
A potent and persistent environmental 
toxin, TCDD binds and activates the aryl 
hydrocarbon receptor (AhR) complex and, 
together with the AhR nuclear translocator, 
binds to dioxin-responsive elements in DNA 
to regulate gene expression and alter signal 
transduction pathways. TCDD diminishes 
both cell-mediated and humoral-mediated 
immunity and increases susceptibility to infec-
tious disease and transplanted tumors (Luebke 
et al. 2006). The degree of immunosuppression 
induced, at a given dose, can be related to 
AhR binding affinity, but the mechanism by 
which this is achieved remains unconfirmed 
(Kerkvliet 2002; Luebke et al. 2006). It has 
been postulated that T-cell alteration occurs 
indirectly through other cells (Kerkvliet 2002), 
possibly during negative selection (Fisher et al. 
2004) or by interaction with more TCDD-
responsive cell types (Camacho et al. 2005; 
Kerkvliet 2002).
Based on the similarity of immunotoxic 
effects (i.e., thymus atrophy) induced by DES, 
DEX, CPS, and TCDD, we hypothesized that 
they would induce an overlapping transcrip-
tional profile in the thymus reflective of gen-
eral toxicity in this organ. In addition, because 
of differences in the reported mechanisms of 
action, we anticipated that each treatment 
would also lead to unique gene expression 
alterations indicative of perturbing specific 
molecular pathways. To test this hypothesis, 
we used an immune-focused array to evaluate 
transcriptional changes in pathways leading 
to altered immune status after treatment with 
DES, DEX, CPS, or TCDD and correlated 
genomic profiles with changes in thymic cell 
populations. Samples were collected under 
conditions demonstrated previously to induce 
thymic atrophy and immuno  suppression 
(reviewed by Dean et al. 1985), when tran-
scriptional analysis might show which path-
ways remained functional and which were 
compromised. Microarray analysis indentified 
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Ba c k g r o u n d: Dysregulation of positive and negative selection, antigen presentation, or apoptosis 
in the thymus can lead to immunosuppression or autoimmunity. Diethylstilbestrol (DES), dexa­
methasone (DEX), cyclophosphamide (CPS), and 2,3,7,8­tetrachlorodibenzo­p­dioxin (TCDD) are 
immunosuppressive chemicals that induce similar immunotoxic effects in the thymus, however, the 
mechanism of toxicity is purported to be different for each compound.
oBjectives: We hypothesized that genomic analysis of thymus after chemical­induced atrophy would 
yield transcriptional profiles that suggest pathways of toxicity associated with reduced function.
Me t h o d s : Female B6C3F1 mice were exposed to these immunosuppressive agents and changes in 
gene expression and immune cell subpopulations were evaluated.
re s u l t s: All four chemicals induced thymic atrophy and changes in both the relative proportion 
and absolute number of CD3+, CD4+/CD8–, CD4–/CD8+, and CD4+/CD8+ thymocytes. The 
most significant impact of exposure to DEX, DES, and CPS was modulation of gene expression in 
the T­cell receptor (TCR) complex and TCR and CD28 signaling pathways; this could represent a 
common mechanism of action and play a pivotal role in lineage commitment and development of 
T cells. Up­regulation of genes associated with the antigen presentation and dendritic cell matura­
tion pathways was the most distinctive effect of TCDD exposure. These elements, which were also 
up­regulated by DEX and DES, contribute to positive and negative selection.
co n c l u s i o n s: Genomic analysis revealed gene expression changes in several pathways that are com­
monly associated with xenobiotic­induced immune system perturbations, particularly those that 
contribute to the development and maturation of thymic T cells.
key w o r d s : cyclophosphamide, dexamethasone, diethylstilbestrol, T cell, thymus, toxicogenomics, 
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249 immune-relevant genes that were differen-
tially expressed in thymus by the high dose of 
one or more of the four chemicals, compared 
with their respective control. 
Initial analyses of this data set were 
described by Patterson and Germolec (2006). 
That report included an enumeration of altera-
tions in gene expression, clustering of expres-
sion profiles, and a limited, low-stringency 
survey of gene ontology. In this article we 
describe changes in the relative proportion 
of T-cell subsets in the thymus by all four 
chemicals and the use of pathway mapping 
techniques to reveal transcription changes in 
several critical pathways associated with T-cell 
development and immune system perturba-
tion. The correlations among genomic analysis, 
cellular pathology, and putative mechanisms of 
action demonstrate the utility of this approach 
as an adjunct to routine toxicity testing for 
hazard identification.
Materials and Methods
Animals and treatment. Female pathogen-free 
B6C3F1 mice were obtained from Taconic 
(Rockville, MD) at 4–8 weeks of age and main-
tained on a 12-hr light/dark cycle at 20–22°C 
in a facility accredited by the Association for 
Assessment and Accreditation of Laboratory 
Animal Care. All experiments were conducted 
under a protocol approved by the Virginia 
Commonwealth University Animal Care and 
Use Committee, and animals were treated 
humanely and with regard for alleviation of 
pain and distress. The animals received Harlan 
Teklad (Madison, WI) Laboratory Diet 7022 
(NIH07) and water ad libitum. At 11–12 
weeks of age, the mice were treated with one 
of four experimental chemicals, DES, DEX, 
CPS (all from Sigma-Aldrich Corp., St. Louis, 
MO), or 2,3,7,8-tetra  choloro  dibenzo-p-dioxin 
(TCDD; Research Triangle Institute, Research 
Triangle Park, NC), at doses that have been 
demonstrated to induce thymic atrophy and 
immuno  suppression, or a matched vehicle, for 
5 days (Table 1). The route, dose, and vehicles 
for all of the chemicals used in this study were 
selected based on reviews included in Dean 
et al. (1982, 1985) and on work published by 
Luster et al. (1981) and van Vliet et al. (1986). 
On day 6, the mice were weighed and eutha-
nized by carbon dioxide asphyxiation, and the 
thymus was excised and weighed. For micro-
array experiments, thymi (n = 4) were stored 
in RNAlater (Ambion, Austin, TX) at –20°C 
until RNA isolation.
RNA isolation and amplification. Total 
RNA was extracted via the Qiagen RNeasy 
kit (Qiagen, Valencia, CA); evaluated by 
absorbance 260/280, gel electrophoresis, and 
Agilent 2100 Bioanalyzer analysis (Agilent 
Technologies, Palo Alto, CA); and amplified 
and purified using the Ambion Illumina RNA 
amplification kit according to the manufac-
turer’s instructions. Briefly, 400 ng of total 
RNA was reverse transcribed to cDNA, which 
was transcribed to cRNA and labeled with 
biotin-16-UTP. The cRNA was quantified 
using the RiboGreen RNA Quantitation Kit 
(Molecular Probes, Eugene, OR).
Microarray. Labeled cRNA samples were 
hybridized to a custom Illumina Sentrix 
Array Matrix (Illumina, Inc., San Diego, CA) 
for 16–18 hr at 55°C, following the manu-
facturer’s instructions. The matrix contains 
oligonucleotide arrays, consisting of 698 
genes selected to reflect responses relevant to 
immune function plus housekeeping genes 
[two 50-mer probes/gene; see Supplemental 
Material, Table 1 (doi:10.1289/ehp.1002358)] 
and 12 negative control sequences (710 genes 
total), arranged in a 96-well design. The arrays 
were washed, blocked with casein, incubated 
with streptavidin-Cy3, dried, and scanned on 
the Illumina BeadArray Reader GX.
Microarray data analysis. Microarray data 
were analyzed using Illumina BeadStudio soft-
ware and Ingenuity Pathway Analysis (IPA; 
version 8.0; Ingenuity Systems, Redwood 
City, CA). In BeadStudio, intensity data 
from the BeadArray Reader were normalized 
using a rank invariant algorithm with a lin-
ear scaling factor, determined by the rank-
invariant genes. Differential expression (DIFF) 
of each probe was evaluated using an error 
model that calculates a p-value as a function 
of intensity differential and biological, techni-
cal, and nonspecific variation. A DIFF score 
of ± 20 corresponds to a p-value of 0.01; 
DIFF scores of corresponding probes were 
averaged, and concordance between probes 
was calculated. Detection scores calculated 
using negative control sequences as a reference 
were used to distinguish true expression from 
background noise. Only genes for which the 
absolute value of the DIFF score ≥ 20 and 
that had concordance and detection scores 
≥ 0.95 were stratified by functional and path-
way charac  teri  za  tion in IPA. The Ingenuity 
Pathway Knowledge Base was used as the ref-
erence set. Fisher’s exact test was used to cal-
culate a p-value determining the probability 
that the association between the genes in the 
data set and the function or pathway would be 
explained by chance alone.
Flow cytometric analysis. Thymocytes 
(n = 8 mice) were isolated and cell surface 
markers quantified as previously described 
(Guo et al. 2006). Single-cell suspensions 
were incubated with appropriate mono  clonal 
antibodies (BD Pharmingen, San Diego, 
CA) and propidium iodide (PI). Fluorescein 
isothio  cyanate (FITC)–conjugated CD3, 
phycoerythrin-conjugated CD4, and FITC-
conjugated CD8a were used to detect specific 
cell populations, which were counted on a 
Becton Dickinson FACScan Flow Cytometer 
(BD Biosciences Immunocytometry Systems, 
San Jose, CA). Nonviable cells and red blood 
cells (RBCs) were eliminated using a gate 
setting that excluded PI fluorescence and a 
forward scatter threshold above RBC size. 
For each sample, 5,000 PI-negative events 
were counted. Raw data were analyzed 
using CellQuest software (BD Biosciences 
Immunocytometry Systems). Homogeneity 
Table 1. Animals and treatment.
Chemical
Treatment DES DEX CPS TCDD
High dose 8.0 mg/kg/day 5.0 mg/kg/day 50.0 mg/kg/day 3.0 μg/kg/day
Low dose 0.8 mg/kg/day 0.5 mg/kg/day 5.0 mg/kg/day 0.3 μg/kg/day
Vehicle Corn oil Ethanol/saline Phosphate- buffered saline Corn oil
Route of exposure Subcutaneous injection Intraperitoneal injection Intraperitoneal injection Gavage
Female B6C3F1 mice 11 to 12 weeks of age were used for microarray (n = 4) and immune assays (n = 8). For all treat-
ments, mice were dosed once daily for 5 consecutive days at the specified concentration.
Figure 1. Three indicators of toxicity, body weight, thymus weight, and thymus cell number, measured 
to evaluate acute toxicity and thymic atrophy after low dose (A) or high dose (B) of immunosuppressive 
agents (percent control; mean ± SE, n = 8). 
*p ≤ 0.05; **p ≤ 0.01 versus matched control.
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was determined using Bartlett’s test. 
Homogeneous data were evaluated using a 
parametric analysis of variance and Dunnett’s 
t-test. Nonhomogeneous data were evaluated 
using a non  parametric analysis of variance 
and the Wilcoxon rank sum test.
Results
General parameters of toxicity and alterations 
in thymic lymphocyte populations. Consistent 
with published literature, all four chemicals 
induced thymic atrophy, as evidenced by sig-
nificantly decreased organ weight and cellu-
larity compared with the appropriate control 
(Figure 1). We observed a 5% decrease in 
body weight in the low-dose DEX group; 
other  wise, treatment did not affect body 
weight. At the high dose, all four chemicals 
induced an elevation in the percentage of 
CD3+, CD4+/CD8–, and CD4–/CD8+ cells in 
the thymus (Table 2). In contrast, at the high 
dose, all four chemicals decreased the total 
number of CD4+/CD8– cells; DEX, CPS, 
and TCDD decreased the total number of 
CD3+ cells; and DEX and CPS decreased the 
total number of CD4–/CD8+ cells, reflecting 
overall thymic atrophy. The percentage and 
total numbers of CD4+/CD8+ cells were sup-
pressed by DEX, DES, and CPS at both the 
high and low doses and by TCDD at the high 
dose. Low-dose TCDD also suppressed the 
total number of CD4+/CD8+ cells. Changes 
in the number and proportion of these popu-
lations suggest alterations in T-cell develop-
ment and differentiation processes and in the 
availability of mature, functional T-helper and 
cytotoxic T lymphocytes (CTLs) for release 
into circulation. We also used two splenic 
T-cell functional assays to pheno  typically 
anchor observed changes in gene expression 
with T-cell recognition and proliferative capa-
bility (Patterson et al. 2006). DES, DEX, and 
CPS, but not TCDD, suppressed T-cell pro-
liferation in response to antibody directed 
against CD3 and to allogeneic leukocytes at 
8.0, 5.0, and 50.0 mg/kg/day, respectively, 
and at 0.8 mg/kg/day DES, confirming the 
suppression of functional immune responses 
by these compounds under the conditions of 
this study.
Global gene expression. Seventeen genes 
(Ccnd3↓, Tcf7↓, Cdk2↓, Gfi1↓, Lat↓, 
Ifngr1↓, Capn2↑, Ifi16↑, Pbef1↑, Gpx3↑, 
Tyrobp↑, Klf2↑, Casp1↑, Fcer1g↑, Fcgr3↑, 
Apoe↑, Ly6a↑) associated with T-cell develop-
ment and differentiation, cellular homeo-
stasis, and apoptosis, proliferation, and cell 
cycle regulation were differentially expressed 
(Illumina DIFF score, |≥ 20|; concordance 
and detection scores ≥ 0.95) by the high dose 
of all four chemicals. High-dose exposure   
to TCDD and CPS altered 73 and 98 genes, 
respectively; however, low-dose exposure 
altered very few genes (TCDD; 8 genes; 
CPS; 2 genes). Conversely, exposure to DEX 
and DES resulted in genes altered at the low 
dose only (DEX, 21 genes; DES, 21 genes), 
genes altered at both low and high doses 
(DEX, 149 genes; DES, 99 genes), and genes 
altered at the high dose only (DEX, 64 genes; 
DES, 46 genes). A complete list of all dif-
ferentially expressed genes is included in 
Supplemental Material, Table 2 (doi:10.1289/
ehp.1002358).
We mapped differentially expressed 
genes to pathways using IPA (for detailed 
lists, see Supplemental Material, Table 3A–C 
(doi:10.1289/ehp.1002358)]. The criteria 
for pathway inclusion were at least three dif-
ferentially expressed genes and a p-value of 
≤ 0.01 (Figure 2). The criteria for function 
inclusion were a p-value of ≤ 0.01 and a mini-
mum of five genes for the global gene set or 
three genes for the common and unique gene 
sets [see Supplemental Material, Tables 3B,C 
and 4 (doi:10.1289/ehp.1002358)]. Because 
of the specific and directional nature of path-
ways, we chose them as the focus for our 
analyses. We gave more weight to pathways 
with strong trends in expression patterns (i.e., 
most genes similarly regulated), alterations in 
related steps, altered receptors, or groups of 
genes with broad-reaching effects and to path-
ways altered by multiple chemicals.
T­cell–related pathways. At the high 
dose, DEX, DES, and CPS down-regulated 
genes in the TCR complex (CD3d, CD3e, 
CD3g) and profoundly affected three path-
ways anchored to the TCR: TCR signaling, 
CD28 signaling in T-helper cells, and CTL 
mediated apoptosis of target cells [Figure 2; 
see also Supplemental Material, Table 3A,B 
(doi:10.1289/ehp.1002358)]. TCDD expo-
sure did not affect the TCR. Twelve genes in 
the TCR signaling pathway, including CD3, 
CD4, and CD8, were down-regulated by DEX 
(both doses), DES (both doses), and CPS 
(high dose); this group of genes also plays 
a key role in other T-cell–related pathways. 
The TCR signaling pathway scored the lowest 
p-value and included the largest number of 
genes altered in the DES and CPS gene sets. 
CD28 is a costimulatory protein for TCR sig-
naling; CTLA-4 binds to the same molecules 
but transmits an inhibitory signal. Both path-
ways flow into the TCR signaling pathway. 
All four chemicals altered these pathways. 
DEX (both doses), DES (both doses), and 
CPS (high dose) down-regulated seven genes 
common to the TCR, CD28, and CTLA-4 
pathways, including CD28, but no chemical 
altered CTLA-4. TCDD (high dose) and DEX 
(both doses) up-regulated an Fc-receptor gene 
associated with antigen binding and a small 
group of histocompatibility genes associated 
with antigen presentation. TCR genes were 
also a key component of the CTL-mediated 
apoptosis of target cells pathway, along with 
a group of apoptosis genes altered by DEX 
(high dose). The T-helper cell differentia-
tion pathway included the Fc-receptor (↑, 
DEX, DES, CPS, TCDD), CD28 (↓, DEX, 
Table 2. Lymphoid cell populations in the thymus (mean ± SE, n = 8).
Percent total cellsa Cells/thymus × 106b
Exposure CD3+ CD4+/CD8– CD4–/CD8+ CD4+/CD8+ CD3+ CD4+/CD8– CD4–/CD8+ CD4+/CD8+
DEX
Vehicle 14.2 ± 0.5 11.9 ± 0.2 2.7 ± 0.1 78.9 ± 0.2 23.6 ± 1.3 19.8 ± 1.1 4.5 ± 0.3 131.3 ± 0.6
0.5 mg/kg/day 37.0 ± 1.5** 29.3 ± 1.0** 8.4 ± 0.4** 34.6 ± 2.4** 18.9 ± 1.6* 14.9 ± 1.2** 4.3 ± 1.4 18.2 ± 2.7**
5 mg/kg/day 31.4 ± 2.2** 19.7 ± 2.3** 8.0 ± 1.0** 0.5 ± 0.2** 6.2 ± 0.7** 4.0 ± 0.7** 1.6 ± 0.3** 0.1 ± 0.1**
DES
Vehicle 13.5 ± 0.3 12.7 ± 0.2 2.4 ± 0.1 79.7 ± 0.3 21.2 ± 1.2 20.1 ± 1.2 3.9 ± 0.3 126.0 ± 7.8
0.8 mg/kg/day 35.9 ± 1.6** 31.1 ± 1.2** 7.6 ± 0.5** 51.1 ± 2.2** 19.3 ± 0.8 16.7 ± 0.8 4.0 ± 0.2 28.6 ± 3.4**
8 mg/kg/day 50.9 ± 2.9** 42.3 ± 2.2** 10.6 ± 0.7** 32.9 ± 3.4** 19.5 ± 1.3 16.3 ± 1.2* 4.0 ± 0.3 13.5 ± 2.2**
CPS
Vehicle 14.0 ± 0.6 11.4 ± 0.5 2.6 ± 0.1 78.3 ± 0.9 18.6 ± 1.5 15.2 ± 1.1 3.5 ± 0.3 105.7 ± 10.6
5 mg/kg/day 15.4 ± 0.5 12.5 ± 0.3* 3.2 ± 0.2* 73.7 ± 0.7** 13.9 ± 2.2* 11.2 ± 0.9* 2.8 ± 0.2 66.4 ± 5.9**
50 mg/kg/day 65.6 ± 4.0** 44.6 ± 3.1** 13.1 ± 1.2** 4.4 ± 2.3** 12.3 ± 1.1** 8.3 ± 0.8** 2.4 ± 0.3* 0.7 ± 0.4**
TCDD
Vehicle 15.2 ± 0.2 12.6 ± 0.3 3.0 ± 0.1 78.1 ± 0.6 23.1 ± 0.5 19.1 ± 0.4 4.6 ± 0.2 118.7 ± 2.4
0.3 μg/kg/day 14.9 ± 0.3 11.7 ± 0.3 3.0 ± 0.1 79.1 ± 0.5 18.3 ± 1.4* 14.4 ± 1.2** 3.6 ± 0.3 96.5 ± 6.6**
3 μg/kg/day 19.7 ± 0.7** 14.7 ± 0.8* 4.6 ± 0.2** 72.0 ± 1.3** 17.2 ± 1.1** 12.8 ± 0.9** 4.0 ± 0.3 63.4 ± 4.6**
aValues represent percentage gated lymphocyte population using CellQuest software. bPercent values and cell counts were used to calculate the total number of each cell population 
in the thymus. *p ≤ 0.05, **p ≤ 0.01, versus matched control.Frawley et al.
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DES, CPS), and histocompatibility (↑, DEX, 
TCDD) genes, but no other genes altered 
in the TCR or CD28 signaling pathways. 
Four cytokine receptors in the T-helper cell 
differentiation pathway were also altered by 
DEX. All four chemicals up-regulated recep-
tor components (Fcer1g, Tyrobp) in the activa-
tion arm of the NK cell signaling pathway, 
and DEX, DES, and CPS down-regulated 
additional genes, including Zap70, a protein 
kinase that serves as a focal point for path-
way signaling. All four chemicals altered func-
tion genes associated with T-cell proliferation 
and develop  ment, and DEX, DES, and CPS 
altered genes associated with T-cell activation 
and apoptosis [see Supplemental Material, 
Table 4 (doi:10.1289/ehp.1002358)].
B­cell receptor signaling/B­cell functions.   
B- and T-cell signaling pathways have many 
molecules in common. Accordingly, the B-cell 
receptor signaling pathway was significantly 
altered by DEX (both doses), DES (both 
doses), and CPS (high dose) (Figure 2), with 
more than one-half of the altered genes, includ-
ing receptor B220/Ptprc, down-regulated. 
DEX, DES, and CPS also altered several genes 
that affect the quantity of B cells produced.
Antigen presentation and dendritic cell 
pathways. The most distinctive effects of 
TCDD exposure were up-regulation of the 
antigen presentation and dendritic cell (DC) 
maturation pathways. DEX and DES similarly 
altered these pathways, and CPS altered the 
DC maturation pathway (Figure 2). The most 
potent chemicals were DEX (both doses) and 
TCDD (high dose), up-regulating genes in 
the CD8+ and CD4+ arms of the antigen pre-
sentation pathway, major histo  compatibility 
(MHC) I (B2m) and MHC II (CD74, HLA-
DMA, HLA-DMB, HLA-DQA1, HLA-DQB1, 
HLA-DRA, HLA-DRB1) mole  cules, and three 
Fc receptors. At the high dose, all four chemi-
cals also altered a related pathway, crosstalk 
between dendritic and NK cells, and gen-
eral function categories related to quantity 
and chemotaxis of antigen-presenting cells 
(APCs); and DEX altered additional APC 
functions.
Other pathways. We observed several 
changes in gene expression in inter  leukin 
(IL) and growth factor pathways [Figure 2; 
see also Supplemental Material, Table 3A 
(doi:10.1289/ehp.1002358)], most notably 
in receptors and in Janus kinases and signal 
transducers and activators of transcription 
molecules, which transmit signals from recep-
tor to nucleus. DEX, primarily, and at least 
one other chemical altered receptor(s) in the 
IL-4, IL-10, IL-6, IL-15, interferon, trans-
forming growth factor-β, and chemokine 
signaling pathways. DEX, DES, and CPS 
altered chemokine ligands, and DEX, DES, 
and TCDD altered several histocompatibility 
genes in the IL-4 pathway. Additionally, DEX 
altered an IL-2 receptor, and genes associated 
with the RelB arm of the nuclear factor κB 
signaling pathway. DEX (high dose) had the 
most profound effect on the apoptosis signal-
ing pathway, altering nine genes, including 
Fas, Bcl2, and caspases 2, 3, and 6. TCDD 
and low-dose DEX also modulated this path-
way, although to a smaller degree. Although 
DES and CPS did not significantly alter the 
apoptosis signaling pathway, they did modu-
late the function categories of T-cell prolifera-
tion and apoptosis. Pathways and functions 
affected by gene alterations common to three 
chemicals or unique to one chemical are pre-
sented in Supplemental Material [Table 3B,C 
(doi:10.1289/ehp.1002358)].
Discussion
Exposure to environmental agents can com-
promise a number of immunological func-
tions. In recent years, genomics has been 
used as an investigational tool to identify bio-
markers and profiles indicative of disease and 
toxicity and to understand mechanisms of 
action (Auerbach et al. 2010; Boverhof et al. 
2009). Future directions for toxicogenomics 
studies include coupling genomic data with 
systems biology and population exposure in 
full risk assessment studies, using surrogate tis-
sues (blood) to establish concordance between 
target and nontarget tissues, and developing 
genomic screening strategies to predict toxicity 
before adverse pathology is evident (Cui and 
Paules 2010; Heinloth et al. 2004). Stremmel 
et al. (2005) and Heinloth et al. (2004, 2007) 
demonstrated that microarray, although gen-
erally less sensitive than reverse-transcriptase 
polymerase chain reaction but encompass-
ing a significant portion of the genome, can 
detect subtle changes reflecting biological 
behavior in dysfunctional murine T cells and 
toxicant-exposed rat liver, respectively, when 
more traditional methods (flow cytometry, 
enzyme-linked immunosorbent assay, histol-
ogy, and clinical chemistry) did not detect dif-
ferences. We postulated that profiling genetic 
alterations in thymus after damage would 
help identify the major immune pathways 
that were compromised by chemical expo-
sure, generate valuable information regarding 
Figure 2. Global alterations in canonical pathways: significance scores (–log of p-value), calculated using 
Fisher’s exact test, for IPA pathways plotted for DES, DEX, CPS, and TCDD. The solid line at –log(p-value) 
of 2 represents a significance threshold at p = 0.01.
T-cell receptor signaling
CD28 signaling in T-helper cells
CTL mediated apoptosis
CTLA4 signaling in CTL cells
T-helper cell differentiation
NK cell signaling
B-cell receptor signaling
Dendritic cell maturation
Antigen presentation
Crosstalk, dendritic and NK cells
Apoptosis signaling
Primary immunodeﬁciency signaling
Communication, innate and adaptive
IL-4 signaling
IL-10 signaling
IL-6 signaling
05 10
–Log (p-value) –Log (p-value)
20 20 15 15 10 5 0
DEX
DES
TCDD
CPS
Pathway name Low dose High doseChemical-induced changes in gene expression
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 3 | March 2011  375
potential mechanisms of action, and elucidate 
transcriptional profiles that could contribute 
to hazard identification.
DEX and DES induced similar gene 
expression patterns at both low and high 
doses. TCDD and CPS induced significant 
transcriptional changes primarily at the high 
dose. Although the magnitude of the changes 
induced by DEX and DES increased at the 
high dose, the same biological pathways, and 
key gene groups, were differentially expressed 
at both doses. Heinloth et al. (2004) have pro-
posed that such a pattern attests to the sensitiv-
ity of microarray as a biologically relevant end 
point and indicator of potential adverse effects. 
DEX had the most significant and widespread 
effect on gene expression, although all treat-
ments altered genes associated with T-cell pro-
liferation, development, and apoptosis. This 
is consistent with the observed reductions in 
thymic weight and cellularity and the total 
numbers of all T-cell populations measured, 
as well as the selective and maturational events 
that occur in the thymus. Apoptosis is a critical 
process in the deletion of autoreactive T cells 
(Chaplin 2010). Individual chemicals regu-
lated caspases 2 and 3, Fas, and members of 
the tumor necrosis factor receptor and B-cell 
lymphoma 2 families, focal points in death-
receptor–mediated apoptosis. Many of the 
genes differentially expressed by all four treat-
ments (high dose), specifically Ccnd3 (Sasaki 
et al. 2007), Fcer1g (Shores et al. 1998), Fcgr3 
(Lynch 2000), Gfi1 (Yucel et al. 2003), Lat 
(Chaplin 2010), Ly6a (Bamezai et al. 1995), 
and Tcf7 (Willinger et al. 2006), have been 
associated with T-cell development and dif-
ferentiation in the thymus. ApoE (Laskowitz 
et al. 2000), Capn2 (Squier and Cohen 1997), 
Casp1 (Zhou et al. 2000), Cdk2 (Williams 
et al. 2000), Gfi1 (Pargmann et al. 2007), Ifi16 
(Wei et al. 2003), Ifngr1 (Matthys et al. 1995), 
and Klf2 (Bai et al. 2007) contribute to apop-
tosis, proliferation, and cell cycle regulation, 
which are key components of negative selec-
tion. Collectively, these genes affect each stage 
of thymocyte development from the double-
negative stage through release from the thymus 
into circulation. Dysregulation of these genes 
can lead to maturation arrest and inappropri-
ate selection and apoptosis, and our findings 
support the utility of gene expression data to 
identify chemicals that may target the thymus.
The most significant effect induced by 
DEX, DES, and CPS was down-regulation 
of genes in the TCR complex and the TCR 
signaling and CD28 signaling pathways. This 
may represent a common mechanism for 
DEX, DES, and CPS and distinguish them 
from TCDD, which did not have an effect on 
the expression of the TCR complex or signal-
ing. TCDD did alter the CD28 signaling path-
way via histocompatibility genes. DEX, DES, 
and CPS down-regulated CD3d, CD3e, and 
CD3g, as well as the coreceptors CD4, CD8a 
and CD8b, and CD28. Several models have 
been proposed to track the evolution of thymic 
cells from CD4+/CD8+ through intermediate 
phenotypes to mature, functional T-helper cells 
and CTLs. One commonality among these 
models is the increase in TCR/CD3 expression 
at critical junctures in lineage commitment, 
followed by up- and down-regulation of the 
coreceptors CD4 and CD8 (Kydd et al. 1995; 
Marodon and Rocha 1994). High levels of 
CD3 are required (Kydd et al. 1995), and loss 
of the required molecules blocks developmental 
progression and results in thymocyte apoptosis 
(Killeen and Littman 1996). Mutation or sup-
pression of kinases and other molecules has also 
been associated with signaling errors during 
selection processes that lead to impaired thy-
mocyte development and alterations in CD4+ 
and CD8+ cell populations (Rudd et al. 2006). 
In our studies, each of the four chemicals tested 
induced suppression of both total number and 
percentage of CD4+/CD8+ precursor cells and 
the total number of CD4+/CD8– cells. DEX 
and CPS exposure also led to a decrease in the 
number of CD4–/CD8+ cells, whereas the per-
centages of CD3+, CD4+/CD8–, and CD4–/
CD8+ cells were increased by all chemicals. 
The degree to which any gene or set of genes 
controls the outcome of T-cell maturation has 
not been definitively established. However, it 
is possible that the down-regulation of CD3, 
CD4, CD8, and the TCR signaling pathway 
by DEX, DES, and CPS could impair T-cell 
development, leading to a loss of precursor 
cells by apoptosis and subsequent reduction in 
the number of mature T cells.
A minority cell population in the thy-
mus, thymic B cells, found primarily in the 
medulla, are specifically adapted to the pro-
cesses of negative selection and contribute to 
the repertoire of developing T cells (Spencer 
et al. 1992). DEX, DES, and CPS, but not 
TCDD, altered a common set of genes associ-
ated with the B-cell signaling pathway and 
B-cell proliferation and quantity, reflecting 
the interaction of B cells and T cells in func-
tional and efficient thymic maturation.
The thymus houses a diverse collection 
of DCs and APCs that present MHC-bound 
self-antigens to developing T cells and induce 
negative selection and apoptosis in potentially 
autoreactive T cells (Evans et al. 2008). The 
expression patterns in the antigen presentation 
pathway were virtually identical for DEX and 
TCDD, suggesting a common mechanism 
of action. Both MHC I and MHC II genes 
were up-regulated. These distinct groups of 
genes, along with Fc receptor genes, were the 
major genes altered by TCDD and DEX in 
the DC maturation pathway. The reported 
effects of DEX on function and T-cell inter-
action with DCs vary with the conditions of 
exposure and type of DC studied (Butts et al. 
2007; Matyszak et al. 2000). Modulation of 
pathways associated with antigen presentation 
was the most significant effect induced by 
TCDD in this study, whereas the T-cell sig-
naling pathway was unaffected. Toxic insults 
to APC populations, and expression of MHC 
molecules in particular, can adversely affect 
T-cell function and activity. For example, 
TCDD altered the CD28 signaling pathway 
via MHC and Fc genes. TCDD has been 
shown to have direct effects on APC from 
several tissues, altering cell number, differ-
entiation, activation, expression of MHC II, 
and the interaction of DCs with T cells (Lee 
et al. 2007; Vorderstrasse et al. 2003), and to 
alter expression of several genes involved in 
negative selection and apoptosis in the thy-
mus (Fisher et al. 2004). It has been proposed 
that the inappropriate activation of cells, as 
is suggested both in in vivo studies and our 
gene expression data, may be the more signifi-
cant mechanism for TCDD-induced immu-
notoxicity, rather than a direct suppression 
of immune functions (Kerkvliet 2002). This 
inappropriate activation of cells could lead 
to the thymic atrophy and immune system 
dysregulation that occurs after TCDD treat-
ment, and may represent a novel mechanism 
of action for TCDD.
Conclusions
The transcriptional profiles of DEX, DES, 
CPS, and TCDD identified a number of 
immune pathways and functions that were 
modulated after chemical exposure. Consistent 
with the thymic atrophy and changes in thy-
mic lymphocyte populations, the constellation 
of pathways affected suggests dysregulation of 
T-cell development in the thymus and func-
tion of mature T cells upon release. Although 
only DEX and TCDD had a significant 
impact on the apoptosis signaling pathway, 
each of the four chemicals altered genes asso-
ciated with apoptosis function, a critical fac-
tor in T-cell selection. The most significant 
observations were the strong down-regulation 
of the TCR complex and the TCR and CD28 
signaling pathways by DEX, DES, and CPS 
and up-regulation of the antigen presentation 
and DC maturation pathways by TCDD, in 
particular, and by DEX and DES. Consistent 
with published research, these findings sug-
gest that DEX, DES, and CPS act primarily 
through direct action on developing T cells in 
the thymus, whereas TCDD acts via an alter-
nate mechanism. The full mechanism of action 
of a chemical is multifactorial and dependent 
upon the tissue and conditions of exposure. 
However, genomic analysis can be a useful tool 
in evaluating the most significant immune 
system perturbations induced and identify-
ing those chemicals that may have potential 
to affect human health through alteration of 
functional immunity.Frawley et al.
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